Evaluation of antibacterial potential of bilirubin nanoparticles against Staphylococcus aureus and Escherichia coli
https://doi.org/10.17586/2220-8054-2022-13-3-342-348
Abstract
Antimicrobial resistance is a major emerging clinical and public health issue across the globe. Nanotechnology is an emerging eld and developing area of scienti c interest in the world. Earlier reports showed in vivo antibacterial activity of bilirubin. Therefore, in present study, bilirubin nanoparticles (BNP) were synthesized of ∼100 - 150 nm, spherical shape and negative charge. Antibacterial activity of BNPs at different concentrations (0.03, 0.1 and 0.3 %) was evaluated by agar well diffusion method against the gram-positive i.e. S. aureus and gram-negative i.e. E. coli bacteria. Tetracycline and enro oxacin used as positive control. Tetracycline and Enro oxacin at different concentrations exhibited zones of inhibition against both S. aureus and E. coli . However, BNPs as well as bulk bilirubin showed no in vitro antibacterial effect on S. aureus and E. coli , however, testing by broth method and at higher concentration as well as against other microorganisms can be explored in future.
About the Authors
D. J. Kamothi
Lala Lajpat Rai University of Veterinary and Animal Sciences
Russian Federation
Russian Federation
V. Kant
Lala Lajpat Rai University of Veterinary and Animal Sciences
Russian Federation
Russian Federation
V. Kumar
Lala Lajpat Rai University of Veterinary and Animal Sciences
Russian Federation
Russian Federation
V. G. Joshi
Lala Lajpat Rai University of Veterinary and Animal Sciences
Russian Federation
Russian Federation
R. Chhabra
Lala Lajpat Rai University of Veterinary and Animal Sciences
Russian Federation
Russian Federation
References
1. World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. No. WHO/EMP/IAU/2017.11, World Health Organization, 2017.
2. Aslam B., Wang W., et al. Antibiotic resistance: a rundown of a global crisis. Infect. Drug Resist., 2018, 11, P. 1645-1658.
3. Lee Y., Kim H., et al. Bilirubin nanoparticles as a nanomedicine for anti-in ammation therapy. Angew. Chem.Int. Ed., 2016, 55 (26), P. 7460-7463.
4. Wang W. W., Smith D.L., Zucker, S. D. Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats. Hepatology, 2004, 40 (2), P. 424-433.
5. Santangelo R., Mancuso C., et al. Bilirubin: An Endogenous Molecule with Antiviral Activity in vitro. Front. Pharmacol., 2012, 3, 36.
6. Buyukasik Y., Akman U., et al. Evidence for higher red blood cell mass in persons with unconjugated hyperbilirubinemia and Gilbert’s syndrome. Am. J. Med. Sci., 2008, 335, P. 115-119.
7. Terzi H.A., Kardes H., et al. The antibacterial effects of bilirubin on gram-negative bacterial agents of sepsis. Biomed. Res., 2016, 27, P. 207-209.
8. Perez C., Pauli M., Bazerque P. An antibiotic assay by agar-well diffusion method. Acta Biol. Med. Exp., 1990, 15, P. 113-115.
9. Kamothi D.J., Kant V., et al. Novel preparation of bilirubin-encapsulated pluronic F-127 nanoparticles as a potential biomaterial for wound healing. Eur. J. Pharmacol., 2022, 919, 174809.
10. Shaarani S., Hamid S.S., Mohd Kaus N.H. The In uence of Pluronic F68 and F127 Nanocarrier on Physicochemical Properties, In vitro Release, and Antiproliferative Activity of Thymoquinone Drug. Pharmacogn. Res., 2017, 9 (1), P. 12-20.
11. Lanone S., Bloc S., et al. Bilirubin decreases nos2 expression via inhibition of NAD (P) H oxidase: implications for protection against endotoxic shock in rats. Faseb J., 2005, 19 (13), P. 1890-1892.
12. Hansen R., Gibson S., et al. Adaptive response of neonatal sepsis-derived Group B Streptococcus to bilirubin. Sci. Rep., 2018, 8 (1), 6470.
Review
For citations:
Kamothi D.J., Kant V., Kumar V., Joshi V.G., Chhabra R. Evaluation of antibacterial potential of bilirubin nanoparticles against Staphylococcus aureus and Escherichia coli. Nanosystems: Physics, Chemistry, Mathematics. 2022;13(3):342-348. https://doi.org/10.17586/2220-8054-2022-13-3-342-348
Views:
3
Email this article 